Allspring Global Investments Holdings, LLC Aerovate Therapeutics, Inc. Transaction History

Allspring Global Investments Holdings, LLC

$59.3 Billion
Q4 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	SELL	$10.8 - $16.91 $10,292 - $16,115	-953 Closed	0 $0
Q1 2022 May 02, 2022	SELL	$8.25 - $18.33 $1,188 - $2,639	-144 Reduced 13.13%	953 $17,000
Q4 2021 Jan 28, 2022	BUY	$9.14 - $21.54 $10,026 - $23,629	1,097 New	1,097 $12,000

Others Institutions Holding AVTE

# of Institutions

Shares Held

30.7M

Call Options Held

186K

Put Options Held

269K

Ra Capital Management, L.P. Boston, MA

9.19M
Shares

$23.4 Million
0.39% of portfolio
Sofinnova Investments, Inc. Menlo Park, CA

3.76M
Shares

$9.58 Million
0.81% of portfolio
Tcg Crossover Management, LLC Palo Alto, CA

2.24M
Shares

$5.71 Million
0.97% of portfolio
Atlas Venture Life Science Advisors, LLC

1.8M
Shares

$4.59 Million
0.79% of portfolio
Braidwell LP Stamford, CT

1.44M
Shares

$3.67 Million
0.21% of portfolio

View Full List

About Aerovate Therapeutics, Inc.

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $62.3M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

More about AVTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.

Account